Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country

View Full Paper
Ask AI
Bookmark
Share

Authors

SSS. SivakumaranVRV RatnamalalaLGLallindra Gooneratne

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows low WHO diagnostic compliance in classical MPNs, highlighting challenges in cytoreductive therapy decisions.

Key Points

  • To evaluate WHO diagnostic conformity and the use of cytoreductive therapy in classical myeloproliferative neoplasms.
  • Retrospective cross-sectional study in hematology units at National Hospital of Sri Lanka.
  • Included patients diagnosed with polycythemia vera, essential thrombocythemia, or primary myelofibrosis from 2018 to 2025.
  • Extracted data on clinical features, diagnostic workup, and treatment outcomes.
  • 76.5% of polycythemia vera met WHO criteria; none of the essential thrombocythemia patients did.
  • 80% of patients received hydroxycarbamide despite not meeting diagnostic criteria.
  • High rates of thrombotic events were observed, especially in polycythemia vera (45.6%).

Cite This Study

Sivakumaran et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8eehttps://doi.org/10.1182/blood-2025-7324
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Single Center’s Experience in the Diagnosis and Treatment of Myeloproliferative Neoplasms2025
  2. 2Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026
  3. 3Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline2023 · 8 citations
  4. 4Access barriers and treatment patterns in Philadelphia-negative myeloproliferative neoplasms (Ph- MPN): Insights from a brazilian physician survey2025
  5. 5Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025